Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/ASO.2006.03.047
Annals of Surgical Oncology 13:45-51 (2006)
© 2006 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cahill, R. A.
Right arrow Articles by Watson, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cahill, R. A.
Right arrow Articles by Watson, R. G.

Original Article

Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core Biopsy

Ronan A. Cahill, AFRCSI1, Daniel Walsh, FFRRCSI2, Rob J. Landers, MRCP3 and R. Gordon Watson, FRCSI1

1 Department of Surgery, Breast Care Unit, Waterford Regional Hospital, Waterford, Ireland
2 Department of Radiology, Breast Cancer Unit, Waterford Regional Hospital, Waterford, Ireland
3 Department of Pathology, Breast Cancer Unit, Waterford Regional Hospital, Waterford, Ireland

Correspondence: Address correspondence and reprint requests to: Ronan A. Cahill, AFRCSI; E-mail: rcahill{at}rcsi.ie

Background: Precise preoperative profiling of breast tumors could facilitate fuller consideration of (neo)adjuvant therapies.

Methods: Diagnostic core biopsy (DCB) accuracy in profiling the primary tumor was prospectively studied in 95 patients with operable breast cancer. The histological type and grade (hematoxylin and eosin staining) and membrane receptor status (semiquantitative immunohistochemistry for estrogen [ER] and progesterone [PR] receptors, as well as Her-2 antigen expression) were assigned by the DCB before surgery. These measures were then compared with those of the definitive surgical specimen available after operation.

Results: DCB correctly ascribed tumor type and grade and ER, PR, and Her-2 receptor status in most cases (correlating exactly in 97.5%, 77%, 68%, 71%, and 60%, respectively) with at least moderate concordance (weighted {kappa}, >.41). When miscategorized, DCB consistently tended to upscore the receptor stain intensity compared with the surgical specimen (22%, 19%, and 27% had higher ER, PR, and Her-2 categorical scores, respectively). ER H-scores correlated best in specimens that stained strongly (224.4 ± 3 vs. 215.5 ± 5) and were significantly higher on DCB in those that stained either moderately (195.6 ± 8.2 vs. 156.8 ± 5.1; P < .0001) or weakly (157.1 ± 24.8 vs. 81.4 ± 4; P = .02). DCB accurately identified all tumors with clinically important ER and Her-2 expression. Furthermore, it promoted three patients into the therapeutically significant range of ER (n = 1) or Her-2 (n = 2) expression. ER negativity on DCB (n = 25) indicated a high-grade tumor (88%), although 11 (44%) patients also overexpressed Her-2. Significant Her-2 expression (n = 16) on DCB predicted the tumor as being poorly differentiated (80%) and both ER and PR negative (67%).

Conclusions: DCB accurately profiles clinically relevant measures of primary tumor cell differentiation. It also reliably categorizes patients with regard to (neo)adjuvant therapy before radical surgery is attempted.

Key Words: Preoperative • Profile • Breast cancer • Core biopsy




This article has been cited by other articles:


Home page
Ann OncolHome page
M. Arnedos, A. Nerurkar, P. Osin, R. A'Hern, I. E. Smith, and M. Dowsett
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
Ann. Onc., July 1, 2009; (2009) mdp234v1.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
E A Rakha and I O Ellis
An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens
J. Clin. Pathol., December 1, 2007; 60(12): 1300 - 1306.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of Surgical Oncology.